Most Recent
Adelaide liquidator Peter Macks has been hit with a three-year ban after a judge found he forged documents to hinder an investigation by the corporate regulator.
Fertility clinic IVF Australia is facing a lawsuit worth "many millions of dollars" launched by the parents of a child born with Pallister-Kilian syndrome, alleging it did not carry out a vital pre-implantation diagnostic test that would have identified the disease.
Further attempts to settle a securities class action against last mile logistics software firm GetSwift would be like flogging a dead horse, a judge has heard as the matter works its way towards a final hearing.
Law firm Atanaskovic Hartnell has failed to postpone its appeal of a ruling over unpaid legal fees until after its senior counsel -- who is stuck in London -- can get a COVID-19 vaccine and return to Australia.
The High Court will consider whether judges should steer clear of barristers outside the court room, after a husband appealed a ruling by a judge who socialised with his wife's lawyer during their two-year divorce trial.
The Morrison government will reportedly make permanent changes to the continuous disclosure laws that were introduced at the height of the COVID-19 pandemic, as part of a wider effort to crack down on class action litigation.
Commonwealth Bank of Australia could be on the hook for a large penalty after the court found the bank engaged in misleading and deceptive conduct and violated its financial services obligations on more than 12,000 occasions by overcharging customers more than $2.2 million in interest.
A tax agent and accountant who conducted multiple tax exploitation schemes between 2011 and 2015 has been hit with a $22.7 million penalty, the largest ever against a tax promotor.
PricewaterhouseCoopers is looking to shut down a class action by irate bondholders of collapsed asset finance lender Axsesstoday Limited over alleged misrepresentations in a $50 million bond offer.
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.